## Drug Monograph

Drug/Drug Class: **Ibandronate sodium injection/ bisphosphonate**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

## Executive Summary

| | |
|---|---|
| **Purpose:** | The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use. |
| **Dosage Forms:** | Ibandronate is available in a 3 mg/3 mL single dose vial containing 3 mg/3 mL ibandronate sodium for injection. |
| **Manufacturer:** | Sun Pharmaceutical Industries Ltd.<br>Acme Plaza, Andheri-Kurla Road Andheri (East), Mumbai - 400 059, India |
| **Indications:** | Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. |
| **Costs:** | $141.74 per vial of Ibandronate sodium MaximumAllowableCost |
| **Summary of Findings:** | This drug is being considered for inclusion in the state specific Preferred Drug List and is a non-preferred agent. |

| | | |
|---|---|---|
| **Status Recommendation:** | ☐ Prior Authorization (PA) Required | ☐ Clinical Edit |
| | ☐ Fiscal Edit | ☒ PDL |
| **Type of PA Criteria:** | ☐ Increased Risk of ADE | ☒ Non-Preferred Agent |
| | ☐ Appropriate Indications | ☐ No PA Required |

Prepared By: Katie Wilbers, PharmD
Date: May 16, 2014

© 2014 Xerox Heritage, LLC All Rights Reserved.